Literature DB >> 15856416

Antifungal properties of surangin B, a coumarin from Mammea longifolia.

Yanshen Deng1, Russell A Nicholson.   

Abstract

The natural product electron transport inhibitor surangin B was examined for its ability to inhibit in vitro mycelial growth and spore germination in several species of fungi. As an inhibitor of mycelial growth, surangin B showed strongest activity against Rhizoctonia solani (IC50 = 3.8 microM) and Botrytis cinerea (IC50 = 11.2 microM). Inhibitory effects were less pronounced in Alternaria dauci, Fusarium oxysporum and Penicillium sp. (IC50 values > 30 microM) and absent in Trichoderma harzianum. Surangin B reduced the level of spore germination in Fusarium oxysporum (IC50 = 2.3 microM) and Botrytis cinerea (IC50 = 1.4 microM), although Alternaria dauci was considerably more tolerant of this coumarin (IC50 = 500 microM). Our results indicate that surangin B may have potential as an antifungal agent.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15856416     DOI: 10.1055/s-2005-864105

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  4 in total

1.  Mammea E/BB, an isoprenylated dihydroxycoumarin protonophore that potently uncouples mitochondrial electron transport, disrupts hypoxic signaling in tumor cells.

Authors:  Lin Du; Fakhri Mahdi; Mika B Jekabsons; Dale G Nagle; Yu-Dong Zhou
Journal:  J Nat Prod       Date:  2010-10-07       Impact factor: 4.050

2.  Monograph: Ochrocarpus longifolius.

Authors:  Roopesh Jain; Archana Tiwari
Journal:  Pharmacognosy Res       Date:  2011-04

3.  Extraction, characterization and biological studies of phytochemicals from Mammea suriga.

Authors:  Mahesha M Poojary; Kanivebagilu A Vishnumurthy; Airody Vasudeva Adhikari
Journal:  J Pharm Anal       Date:  2015-01-19

4.  Down-regulatory mechanism of mammea E/BB from Mammea siamensis seed extract on Wilms' Tumor 1 expression in K562 cells.

Authors:  Methee Rungrojsakul; Trinnakorn Katekunlaphan; Aroonchai Saiai; Chadarat Ampasavate; Siriporn Okonogi; Colleen A Sweeney; Songyot Anuchapreeda
Journal:  BMC Complement Altern Med       Date:  2016-05-18       Impact factor: 3.659

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.